About us

Innovating drug delivery

Cyprumed is a dedicated drug delivery company based in Innsbruck, Austria. Our main focus is on the development of proprietary technology platforms for the oral administration of therapeutic peptides. In addition, we are active in the field of oral delivery of Biopharmaceutics Classification System injectable (BCS Class IV) drugs.

Cyprumed Team

Meet our team

Cyprumed is led by a team of experts, with long-standing experience and a proven track record in research and development of oral drug delivery systems. Our executive team is supported by an advisory board, comprised of a group of former senior executives of the pharma- and biotech industry. Cyprumed also works with a network of experts and specialized service providers in various areas such as business development, IP, bioanalytics, academic research and non-clinical PK studies.

Executive team

Advisory board

Dr. Jürg Meier

Jürg Meier was the Executive Director of the Novartis Venture Fund for eight years. Previously, he was working over 25 years in various international management functions of the former company Sandoz Pharma Ltd., holding positions such as Head of R&D Biochemie GmbH Austria, Head of R&D Sandoz USA and worldwide and President of Sandoz Pharma Japan. During eight years he was a member of the Swiss National Science Foundation and supervised three NCCR programs (National Centers of Competence in Research). Jürg Meier was Chairman of Polyphor AG and of Cardiolynx AG and a Board Member of Tecan AG, BioMed Invest AG and Solvias AG. Today Jürg Meier consults entrepreneurs and start-up companies.

Dr. Ruedi Wäger

Ruedi Wäger was the President and Chief Executive Officer of Aventis Behring L.L.C.. Previously, he was President and Chief Executive Officer of ZLB Central Laboratories, Blood Transfusion Service of Swiss Red Cross, and spent more than 20 years at Sandoz Ltd., where he had consecutive worldwide responsibilities for Strategic Research and Development Planning, Human Resource Management, and Marketing. Ruedi Wäger currently sits on the board of various biopharmaceutical companies. He earned a Ph.D. in Biochemistry from the Swiss Federal Institute of Technology.

Dr. Uwe Jacob

Uwe Jacob was the main founder and first CEO of SuppreMol GmbH. Later he was holding the position of the Chief Scientific Officer and the Chief Development Officer. In parallel Uwe Jacob is teaching biochemistry at the Gene Center, Munich. Before working with SuppreMol he was assistant Professor at the Ludwig Maximilians University of Munich and a group leader at the Max Planck Institute of Biochemistry. Uwe Jacob studied biochemistry at the Medizinische Hochschule Hannover and the University of Southern California. He finalized his PhD thesis in X-ray crystallography in the department of Prof. Huber at the Max Planck Institute of Biochemistry. Afterwards Uwe Jacob continued his career as a post doctoral scientist at Roche Pharmaceuticals where he also finished his habilitation program.


Stay informed about the latest updates from Cyprumed by following our news section.

Want to collaborate?

Are you interested in a possible collaboration? Do you have any questions? We look forward to hearing from you!